Skip to content

Human Subcutaneous Inflammatory Response to Glucose Sensors

Human Subcutaneous infLammatory Response to Glucose Sensors: Impact on the Quality of the Measure

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05755243
Acronym
TISSUESENSOR
Enrollment
24
Registered
2023-03-06
Start date
2022-06-21
Completion date
2023-09-20
Last updated
2023-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Response to Glucose Sensors

Keywords

Enzymatic glucose sensors, foreign body response

Brief summary

The aim of the study is to describe the inflammatory response to enzimatic glucose sensors after 10 days of use and to evaluate the relationship between the magnitude of the FBR (foreign body response) with the accuracy of the sensor (MARD)

Detailed description

Eighteen Type 1 DM patients are going to be included. Primary Objectives 1. To define the intra-individual and inter-individual variability of the macrophage count around the sensor 2. To assess whether there is a relationship between the number of macrophages, fibrosis and MARD of the MCG registry. Secondary Objectives To describe the histology of tissue response. This description will include: 1. HE stain: cell types, arrangement, vascular structures, signs of hemorrhage-clot. Giemsa stain: mast cells. Masson's trichrome stain: str. vascular. 2. Immunohistochemistry: Vascular assessment, characterization of macrophages Each patient will have 1 glucose sensor inserted in the non-dominant arm. During the useful life of the sensor (10), a minimum of 4 capillary blood glucose determinations/day will be performed The sensor has a length of 8 mm and a diameter of 0.4 mm. All the necessary material will be provided, including a control diary to help the patient remember to carry out the self-control and set its time distribution. On the last day of sensor use, it will be removed and a 4-mm punch skin biopsy will be performed 5 minutes later. Tissue samples will be fixed in 4% formaldehyde solution, paraffin blocks made and sectioned. The resulting samples will be stained Semiquantitative determination of lymphocytes, neutrophils, mast cells, macrophages will be performed; fibrin, fibrosis, vascular proliferation and karyorrhexis In all cases, a quantitative immunohistochemical study will be performed with x40 field counting with photographs and grid (Dako omnis with envision system) for: Macrophages The monitor-glucometer will be recovered for download and study of the record. The interstitial glucose - blood pairs will be made with those recorded but not used for callibration. Glucose sensor values and insulin doses will be recover from tha medical application

Interventions

skin biopsy (punch)

Sponsors

Corporacion Parc Tauli
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 1\. Type 1 diabetes of more than 6 months duration, confirmed by positivity for Ab antiGAD 65 2. Be a regular user of a continuous glucose monitoring system 2. To Understand the proposed protocol and acceptance of participation.

Exclusion criteria

* Treatment with drugs that could potentially modify the inflammatory response during the 10 days prior to surgery (non-steroidal anti-inflammatory drugs or corticosteroids, antioxidants or platelet antiaggregants).

Design outcomes

Primary

MeasureTime frameDescription
Number of Macrophages sourronding the sensor10 days
MARD (CGM record for 10 days)10 daysmedian absolute relative difference (BG- Sensor glucose)

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026